Generics 8

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Carfilzomib manufacturers

8 products found

Filters

8 products found

carfilzomib

Vials, injection 60 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #17047
A pharmaceutical manufacturer based in the EU that sells its products in Europe, the Middle East, CIS, LATAM, and Asia. Key production lines are pharmaceuticals, bio and nanopharmaceuticals, medical devices, and nutraceuticals. The main therapeutic area is oncology.

Manufacturer usually replies in 10 days

carfilzomib

Injection, lyophilized 10 mg, 30 mg, 60 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #15176

Manufacturer usually replies in 5 days

carfilzomib

Injection 60 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
India
GMP approvals
WHO
Manufacturer #22283

Manufacturer usually replies in 4 days

carfilzomib

Powder for solution for infusion 60 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
Turkey
GMP approvals
EU GMP
Manufacturer #2722
It originally entered the pharmaceutical industry in 1987, when it introduced blood derivative products to Europe and became the exclusive distributor for prominent European brands. Oncology, hematology, dermatology, radiology, rheumatology, immunology, and OTC products are the seven main therapeutic fields.

Manufacturer usually replies in 6 days

carfilzomib

Vials, injection 60 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17753

Manufacturer usually replies in 10 days

carfilzomib

Vials, lyophilized injection 60 mg - 50 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #31067

carfilzomib

Vials, injection 60 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #30013

Manufacturer usually replies in 2 days

carfilzomib

Injection 30 mg, 60 mg

Dossier type
CTD
Dossier status
Outdated
Country of origin
India
GMP approvals
WHO
Manufacturer #31073

Manufacturer usually replies in 6 days

CARFILZOMIB manufacturers

Carfilzomib is a medication that is used to treat relapsing or refractory multiple myeloma. Patients with these indications are given the drug intravenously. Suppliers of carfilzomib marketed the drug as 10mg, 20mg, and 60mg Kyprolis powders that can be reconstituted into an injectable solution. The developer and sole manufacturer of carfilzomib medications are Onyx Pharmaceuticals (now a subsidiary of Amgen), which first acquired approval to market the drug from the FDA in 2012, and from the EMA in 2015. Currently, it is marketed in numerous countries worldwide, including but not limited to Australia, Brazil, Russia, Canada, Japan, Turkey, Israel, and many EU countries. Notably, Kyprolis is also marketed in India by manufacturer and supplier Dr. Reddy, following a joint commercialization agreement. Popular alternatives to Kyprolis include Revlimid by manufacturer and supplier Celgene and Velcade by Johnson & Johnson. However, due to the complementarity between the two drugs, Kyprolis and Revlimid can be used together as a combined therapy for multiple myeloma patients. Warnings: Follow all Instructions on your medicine package and label. It is wise to tell your healthcare providers about all your medical allergies, illnesses, and all medicines you use. Before taking CARFILZOMIB: You should not use This medical drug if you are allergic to it This drug may also be used for purposes that may not have been listed in this medication guide.

How does CARFILZOMIB work?

The usage of this pharmaceutical substance: Read the Guide and, if available, the Patient Information Leaflet that will be provided by your pharmacist before you start taking CARFILZOMIB. If you have any questions related to this medical remedy, ask your pharmacist or doctor. This pharmaceutical product is a type of inhibitor that works by blocking various myeloma cells from cutting down proteins within the cells. This may cause the development of proteins within various myeloma cells, which may lead to cell death. This pharmaceutical drug is given by injection into a vein by a doctor or a nurse. It is given as instructed by your doctor, usually over 30 minutes or at least over 10 minutes. The dosage is based on your lab tests, body size, response to treatment, and medical condition. This remedy can sometimes produce a severe reaction during and up to 24 hours after the injection. You should tell your health care professional right away if you acquire symptoms such as fever, chills, flushing, joint/muscle pain, trouble breathing, chest pain, or fainting. Side Effects: lightheadedness, dizziness, nausea, diarrhea, vomiting, constipation, and tiredness may occur. If any of these effects get worse or last, tell your pharmacist or doctor fast. To reduce the risk of lightheadedness and dizziness, get up gently when arising from a lying or sitting position. While using this remedy people may have severe side effects. However, your health care professional has prescribed this drug because she or he has judged that the advantage to you is greater than the risk of side effects. Careful monitoring by your health care instructor may lessen your risk.

The Wholesale Price of CARFILZOMIB?

It is obtainable in generic and brand versions. It is not covered by most Medicare and insurance plans, but pharmacy coupons can help balance the price. The retail price for a single sachet of Kyprolis 60mg powder falls into an approximate range of 1,200 EUR to 1,400 EUR. Prices may vary on the pharmacy you visit.

Sourcing the CARFILZOMIB Manufacturers and Suppliers

If you are looking to find manufacturers and suppliers of CARFILZOMIB, locate them quickly using Pipelinepharma's online marketplace. With this convenient B2B platform, you can order types of medications and quantities you require from companies that have passed our stringent vetting and quality control procedures. Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of CARFILZOMIB offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for this substance manufacturer and these substance suppliers that you are looking for. These also enable you to check the dossier status of this medicine, and the GMP approvals of the different variants of CARFILZOMIB. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where CARFILZOMIB is already registered in. Manufacturers also have special, and delivery terms.

Establishing commercial ties

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and ordering process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

Quality Assurance

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen CARFILZOMIB manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.